Vandria
Phase 1We are developing first-in-class small molecules against a novel target to improve mitochondrial function and reduce chronic inflammation to treat age-related diseases.
Founded
2018
Focus
Small Molecules
About
We are developing first-in-class small molecules against a novel target to improve mitochondrial function and reduce chronic inflammation to treat age-related diseases.
Funding History
1Total raised: $2.5M
Seed$2.5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2018
LocationLausanne, Switzerland
StagePhase 1
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile